Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aptevo Therapeutics
Seattle, Washington, United States
- Ownership
- Public · APVO
- Employees
- ~37
- Development stage
- Other
01
Overview
Aptevo Therapeutics has advanced its lead bispecific antibody candidate, APVO436, into Phase 1 clinical studies targeting relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Early data demonstrate encouraging anti-leukemic activity and manageable safety profile.
- Therapeutic areas
- HematologyOncology
- Modalities
- Bispecific monoclonal antibodyBiologic
- Industry
- Biotech
02
Partnerships
Alligator Bioscience
Beyond the preview
Go deeper on Aptevo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aptevo Therapeutics.